PT3101132T - Anticorpo humano anti-transtirretina - Google Patents
Anticorpo humano anti-transtirretinaInfo
- Publication number
- PT3101132T PT3101132T PT157435413T PT15743541T PT3101132T PT 3101132 T PT3101132 T PT 3101132T PT 157435413 T PT157435413 T PT 157435413T PT 15743541 T PT15743541 T PT 15743541T PT 3101132 T PT3101132 T PT 3101132T
- Authority
- PT
- Portugal
- Prior art keywords
- human antibody
- transthyretin
- transthyretin human
- antibody
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014014912 | 2014-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3101132T true PT3101132T (pt) | 2021-12-31 |
Family
ID=53756906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT157435413T PT3101132T (pt) | 2014-01-29 | 2015-01-23 | Anticorpo humano anti-transtirretina |
Country Status (7)
Country | Link |
---|---|
US (2) | US10597440B2 (zh) |
EP (2) | EP3981874A1 (zh) |
JP (2) | JP6517156B2 (zh) |
KR (1) | KR102240417B1 (zh) |
CN (1) | CN106459956B (zh) |
PT (1) | PT3101132T (zh) |
WO (1) | WO2015115332A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
EP3691447A4 (en) | 2017-10-06 | 2021-08-11 | Prothena Biosciences Limited | ANTI-TRANSTHYRETINE ANTIBODIES |
KR102581734B1 (ko) * | 2017-10-06 | 2023-09-22 | 네오토프 뉴로사이언스 리미티드 | 트랜스타이레틴의 검출 방법 |
AU2018375356A1 (en) | 2017-11-29 | 2020-05-14 | Neotope Neuroscience Limited | Lyophilized formulation of a monoclonal antibody against transthyretin |
WO2020003172A1 (en) | 2018-06-26 | 2020-01-02 | Mor Research Applications | Transthyretin antibodies and uses thereof |
IL298135A (en) | 2020-05-12 | 2023-01-01 | Neurimmune Ag | Combined treatment for ttr amyloidosis |
CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
WO2024121156A1 (en) | 2022-12-05 | 2024-06-13 | Neurimmune Ag | Cyclic compounds and their use in assays for detecting antibodies |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4150814B2 (ja) | 2001-07-06 | 2008-09-17 | 財団法人化学及血清療法研究所 | 遺伝子組換えエカリン及びその製造方法 |
US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
US7601351B1 (en) * | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
EP2211889B1 (en) * | 2007-10-25 | 2014-08-20 | The Scripps Research Institute | Antibody-mediated disruption of quorum sensing in bacteria |
AU2008345022B2 (en) * | 2007-12-28 | 2014-11-06 | Prothena Biosciences Limited | Treatment and prophylaxis of amyloidosis |
WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
JP2010195710A (ja) | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
EP3539985A1 (en) | 2012-02-24 | 2019-09-18 | AbbVie Stemcentrx LLC | Anti sez6 antibodies and methods of use |
US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
WO2014124334A2 (en) | 2013-02-08 | 2014-08-14 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
-
2015
- 2015-01-23 EP EP21202742.9A patent/EP3981874A1/en active Pending
- 2015-01-23 KR KR1020167023089A patent/KR102240417B1/ko active IP Right Grant
- 2015-01-23 CN CN201580017230.1A patent/CN106459956B/zh active Active
- 2015-01-23 PT PT157435413T patent/PT3101132T/pt unknown
- 2015-01-23 EP EP15743541.3A patent/EP3101132B1/en active Active
- 2015-01-23 US US15/114,545 patent/US10597440B2/en active Active
- 2015-01-23 WO PCT/JP2015/051860 patent/WO2015115332A1/ja active Application Filing
- 2015-01-23 JP JP2015559913A patent/JP6517156B2/ja active Active
-
2019
- 2019-04-17 JP JP2019078507A patent/JP6759408B2/ja active Active
-
2020
- 2020-02-06 US US16/783,560 patent/US11186630B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3101132A1 (en) | 2016-12-07 |
JP6517156B2 (ja) | 2019-05-22 |
KR20160113208A (ko) | 2016-09-28 |
US20160340419A1 (en) | 2016-11-24 |
JP2019191174A (ja) | 2019-10-31 |
EP3981874A1 (en) | 2022-04-13 |
EP3101132A4 (en) | 2017-09-13 |
WO2015115332A1 (ja) | 2015-08-06 |
CN106459956B (zh) | 2019-12-17 |
US10597440B2 (en) | 2020-03-24 |
CN106459956A (zh) | 2017-02-22 |
JP6759408B2 (ja) | 2020-09-23 |
JPWO2015115332A1 (ja) | 2017-03-23 |
EP3101132B1 (en) | 2021-12-22 |
US11186630B2 (en) | 2021-11-30 |
US20200181250A1 (en) | 2020-06-11 |
KR102240417B1 (ko) | 2021-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL252004A0 (en) | Ether-substituted antibody | |
IL250583A0 (en) | Anti-tigit antibodies | |
SG11201703403TA (en) | Anti-tim-3 antibodies | |
SG11201703346PA (en) | Anti-tim-3 antibodies | |
GB201411320D0 (en) | Antibody construct | |
IL252422B (en) | Effector-deficient anti-cd32a antibodies | |
PT3101132T (pt) | Anticorpo humano anti-transtirretina | |
IL291164A (en) | Anti-nme antibody | |
ZA201701461B (en) | Antibody formulations | |
IL250374A0 (en) | Antibodies against ceramide | |
PL3180356T3 (pl) | Ludzkie przeciwciało anty-fgfr4 | |
GB201410520D0 (en) | Antibody | |
SG11201700922YA (en) | Anti-orai1 antibody | |
IL247988A0 (en) | Antibodies against hpa–1a | |
GB201418776D0 (en) | Antibody | |
GB201413745D0 (en) | Antibody | |
GB201419092D0 (en) | Anti-TIM-3 antibodies | |
GB201419089D0 (en) | Anti-TIM-3 antibodies | |
GB201411319D0 (en) | Antibody | |
GB201417614D0 (en) | Antibodies | |
GB201407535D0 (en) | Antibody Drug - Conjugates | |
GB201414270D0 (en) | Antibodies | |
GB201415526D0 (en) | Antibody Formulations | |
GB201415298D0 (en) | Antibody Formulations | |
GB201405775D0 (en) | Antibodies |